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Abstract
Background
Glucocorticoid Receptor agonists, particularly classic glucocorticoids, are the mainstay
among treatment protocols for various chronic inflammatory disorders, including nasal dis-
ease. To steer away from steroid-induced side effects, novel GR modulators exhibiting a
more favorable therapeutic profile remain actively sought after. Currently, the impact of 2-
(4-acetoxyphenyl)-2-chloro-N-methylethylammonium chloride a plant-derived selective glu-
cocorticoid receptor modulator named compound A, on cytokine production in ex vivo
human immune cells and tissue has scarcely been evaluated.
Methods and Results
The current study aimed to investigate the effect of a classic glucocorticoid versus com-
pound A on cytokine and inflammatory mediator production after stimulation with Staphylo-
coccus aureus–derived enterotoxin B protein in peripheral blood mononuclear cells
(PBMCs) as well as in inferior nasal turbinate tissue. To this end, tissue fragments were
stimulated with RPMI (negative control) or Staphylococcus aureus–derived enterotoxin B
protein for 24 hours, in presence of solvent, or the glucocorticoid methylprednisolone or
compound A at various concentrations. Supernatants were measured via multiplex for pro-
inflammatory cytokines (IL-1β, TNFα) and T-cell- and subset-related cytokines (IFN-γ, IL-2,
IL-5, IL-6, IL-10, and IL-17). In concordance with the previously described stimulatory role of
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superantigens in the development of nasal polyposis, a 24h Staphylococcus aureus–de-
rived enterotoxin B protein stimulation induced a significant increase of IL-2, IL-1β, TNF-α,
and IL-17 in PBMCs and in inferior turbinates and of IL-5 and IFN-γ in PBMCs.
Conclusion
Notwithstanding some differences in amplitude, the overall cytokine responses to methyl-
prednisolone and compound A were relatively similar, pointing to a conserved and common
mechanism in cytokine transrepression and anti-inflammatory actions of these GRmodula-
tors. Furthermore, these results provide evidence that selective glucocorticoid receptor
modulator-mediated manipulation of the glucocorticoid receptor in human tissues, supports
its anti-inflammatory potential.
Introduction
Inflammation involves a systemic immune response of tissues to a plethora of harmful
stimuli—such as bacterial lipopolysaccharides, tumor necrosis factor (TNF)α, irradiation or
viral infection—and is characterized by an activator protein-1 (AP-1)- and/or nuclear factor
κB (NF-κB)-mediated production of several cytokines and chemokines. Both transcription fac-
tors are ubiquitously expressed and form homo- and heterodimers. Whereas AP-1 is both nu-
clear and cytoplasmic, the prototypical NF-κB heterodimer p65-p50 resides mostly in the
cytoplasm of unstimulated cells, with its nuclear localization signal shielded by the NF-κB-
binding inhibitor of NF-κB (IκB). Upon exposure to a stressor, such as TNFα, the activated
IκB kinase (IKK) complex phosphorylates IκB, resulting in the subsequent ubiquitination and
proteasomal degradation of this protein. As such, activated and post-translationally modified
NF-κB is free to travel to the nucleus and activate the gene promoters of multiple pro-inflam-
matory genes via binding to its specific recognition sites and mounting an active enhanceo-
some [1–3]. These AP-1- and NF-κB-enhanced genes are involved in immune responses and
code for cytokines, e.g.interleukin-6 (IL-6), IL-8, IL-1, enzymes, e.g. iNOS and COX-2, and ad-
hesion molecules, e.g. ICAM and VCAM [4,5].
Exemplary, inflammation-based chronic upper airway diseases are common and disabling
afflictions [6,7] for which the current first choice treatments constitute anti-histamines and
topical glucocorticoids [8,9]. Allergic rhinitis, representing an inflammation of the nasal muco-
sa to allergens after a sensitization process, involves histamine, leucotriene and prostaglandin
release by mast cells and cytokine production by T helper (Th)2 cells. Additionally, acute post-
viral and chronic rhinosinusitis, with or without nasal polyps, classify as an inflammatory reac-
tion by Th1, Th2 or Th17 cells and implicate extensive pro-inflammatory cytokine release pro-
cesses [8,9].
Glucocorticoids play a role in a number of biological processes, including development, dif-
ferentiation, metabolism and homeostasis and stress control. In that respect, glucocorticoids
are used as effective anti-inflammatory therapeutics in a variety of inflammation-based afflic-
tions, including allergic rhinitis and nasal polyposis [8–12]. These steroidal glucocorticoids can
bind to their cognate glucocorticoid receptor (GR, NR3C1). This receptor, and member of the
nuclear receptor family, comprises a variable N-terminal activation domain, and an evolution-
ary conserved DNA-binding domain, hinge region and ligand binding domain, the latter of
which contains yet a second activation domain [13]. Mechanistically, naive GR molecules re-
side in a chaperoning complex in the cytoplasm, while a ligand-activated GR translocates into
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the nucleus resulting in specific gene transcription and repression of gene expression. Besides
other gene-activating mechanisms, the classic binding of a ligand-activated GR dimer to a pal-
indromic glucocorticoid-responsive element (GRE) constitutes transactivation. Conversely, the
prototypical transrepression mechanism is characterized by binding of GR to another DNA-
bound transcription factor, such as NF-κB or AP-1 [13,14]. Alternatively, the GR can also in-
hibit gene expression via a negative GRE (nGRE) featuring direct DNA binding of the GR [15].
Different glucocorticoids can have different relative receptor affinities and display different
pharmacokinetic parameters, ultimately affecting their anti-inflammatory activity [16]. More-
over, the use of glucocorticoids is burdened by a detrimental side effect profile, predominately
but not exclusively associated with GR transactivation [17,18]. The adverse effects along with
the occurrence of glucocorticoid insensitive patients [19] continuously drive the search for
more selective GR modulators with a comparable anti-inflammatory or transrepressing power
and with an overall improved therapeutic index. In various reports, compound A (CpdA), a
stabile analogue of the hydroxy-phenyl aziridine precursor found in the Namibian shrub Sal-
sola tuberculatiformis Botschantzev [20], has shown GR-dependent anti-inflammatory actions
with reduced side effects, both in vitro and in vivo [21–25]. Indeed, this plant-derived com-
pound A, i.e. 2-(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride, can bind to
GR and allows GR-mediated transrepression of various cytokines and chemokines via an inhi-
bition of NF-κB activity [21,23]. However, as compound A actively drives GR to a monomer
formation and does not mediate GR Ser211 phosphorylation, compound A does not empower
classic GRE transactivation mechanisms [21–23,26].
Since almost all currently published reports on compound A feature in vitro or murine in
vivo data and since pathophysiological responses are still best analyzed in human subjects or at
least primary cells, we set out to investigate how this selective GR modulator impacts human
cells and tissues, with regard to the secretion of inflammation-regulating cytokines and the pos-
sible induction of cell toxicity. To this end, we studied ex vivo human PBMCs and an ex vivo
human model for challenged nasal inferior turbinate tissue. We measured cytokines derived
from different T helper cells as outcome parameters. To analyze the potential clinical applica-
bility of selective GR modulation, exemplified by compound A, we used the bacterial entero-
toxin Staphylococcus aureus enterotoxin B (SEB) to induce cytokine production in these tissues
and cells, as an established model previously used to investigate human nasal polyposis [27].
Material and Methods
Patients
Nasal tissue was obtained from 9 patients (mean age, 40.7 years; range, 16–62 years; 5 male and
4 female) undergoing septal surgery and/or turbinotomy because of nasal obstruction, a rou-
tine sinus surgery at the Department of Oto-rhino-laryngology of the Ghent University Hospi-
tal. Additional PBMCs were obtained from 6 patients (mean age, 34.0 years; range, 27–41
years; 1 male and 5 female). The ethical committee of the Ghent University Hospital approved
the study (2004/334), and all patients gave their written informed consent before inclusion in
the study. On behalf of the minors in the study, written informed consent was obtained from
the next of kin, caretaker, or guardian. None of the patients received intranasal corticosteroids,
anti-histamines, anti-leukotrienes, oral or intranasal decongestants, or intranasal anti-choliner-
gics within 1 week before surgery, and none of the subjects received oral and/or intramuscular
corticosteroids within 4 weeks before surgery. For female subjects, pregnancy or lactation
was excluded.
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Mechanical disruption and stimulation of human nasal tissue
Preparation of human inferior turbinate tissue was performed, essentially as described [28]. In
short, human nasal tissue was cut in RPMI1640 tissue culture medium (Sigma-Aldrich, Bel-
gium), complemented with 2mM L-Glutamine (Invitrogen, Belgium), 50 IU/ml penicillin,
50mg/ml streptomycin (Invitrogen) and 0.1% BSA (Sigma-Aldrich). Subsequently these pieces
were passed through a mesh to achieve comparable sized fragments (±0.9mm3). After 1h equil-
ibration, the obtained tissue fragments were washed with fresh culture medium, weighed and
resuspended into 48-well plates (BD Falcon; VWR International, Belgium) as 0.04g/ml in 0.5
ml RPMI1640 tissue culture medium, prepared as above. Tissue suspensions were pre-incubat-
ed with either solvent, methylprednisolone (MP) (ranging from 10-4M to 10-11M) or com-
pound A (ranging from 10-4M to 10-11M) for 1 hour at 37°C and 5% CO2. Ensuing, tissue
fragments were stimulated with 0.5 μg/ml (final concentration, fc) Staphylococcus aureus en-
terotoxin B (SEB, Sigma-Aldrich) for 24 hours. The SEB solvent PBS served as a negative
control.
Peripheral blood mononuclear cell (PBMC) analysis
Peripheral blood mononuclear cells (PBMCs) were isolated from anti-coagulated (using
EDTA) human blood by density gradient centrifugation over Ficoll Paque (GE Healthcare)
and consist mainly of monocytes, T cells and B cells and smaller amounts of NK cells and den-
dritic cells of both myeloid and plasmacytoid origin. PBMCs of 10 donors were pre-incubated
with either solvent, methylprednisololone (ranging from 10-7M to 10-5M) or compound A
(ranging from 10-7M to 10-5M) for 1 hour at 37°C and 5% CO2. Ensuing, PBMCs were exposed
to either tissue culture medium or SEB (Sigma-Aldrich) at 0.5μg/ml (fc) for 24 hours. An addi-
tional pre-incubation step with RU486 (20μM) (Sigma-Aldrich) was included for particular
settings in an experiment, as indicated in the figure legend.
Cytokine production analysis
Supernatants of inferior turbinate tissue and PBMC solutions were separated by centrifugation;
aliquots of the supernatants were snap frozen and stored immediately at -20°C until analysis of
cytokines. Concentrations of IL-1β, IL-2, IL-5, IL-6, IL-10 and IL-17, TNFα and/or interferon-
γ (IFN-γ) (detection limits 0.6 to 7.8 pg/ml) were measured using commercially available
Fluorokine MAP Human Cytokine Kits by using the Fluorokine MAP Human Base Kit A
(R&D Systems, MN, USA) following the instructions of the manufacturer, on a Bio-Plex 200
Array Reader (Bio-Rad, Hercules, CA, USA).
Cell viability analyses
To assess possible cell damage and toxicity effects of the used compounds, we used the com-
mercial QuantiChrom Lactate Dehydrogenase Kit (BioAssays Systems, Hayward, CA, USA)
for a colorimetric kinetic determination of lactate dehydrogenase (LDH) activity. The analysis
was performed according to the manufacturer’s instructions. The culture media from PBMCs,
stimulated as indicated in the figure legends, were assessed for released LDH, with a detection
limit from 2 IU/L up to 200 IU/L. Cell apoptosis was assessed by means of an annexin V FITC
assay kit (Cayman Chemical) via FACS analysis gated on the lymphocytes. Propidium iodide
served as a marker of cell death in this assay.
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Statistical analyses
Results are shown +/- standard error. Statistical analysis of the cytokine production analyses
were performed using a Wilcoxon matched-pairs singed-ranks test for paired comparisons cor-
rected for multiple comparisons. The results from the LDH analysis were statistically analyzed
using a Friedman test. The results for the annexin V binding assay were statistically analyzed
using a two-way ANOVA with Bonferroni post-tests. In all assays, P values below 0.05 were
considered to indicate a statistically significant difference.
Results
The impact of compound A and methylprednisolone on Th1 cytokines
To investigate how the selective GR modulator compound A impacts human cells and tissues,
we treated ex vivo human PBMCs and an ex vivo human model for challenged nasal inferior
turbinate tissue with the bacterial enterotoxin Staphylococcus aureus enterotoxin B (SEB), pre-
ceded with a treatment with solvent, compound A (CpdA) or methylprednisolone (MP) in
gradually increasing concentrations. Upon assaying the secreted protein levels of Th1 cytokines
IL-2 and IFN-γ, it was clear that upon SEB stimulation the IL-2 production augments in both
PBMCs and inferior turbinate tissue (Fig 1A and 1B), whilst the IFN-γ production is enhanced
only in PBMCs and not inferior turbinate tissue (Fig 1C and 1D). Considering IL-2, we show
that MP treatment results in a concentration-dependent decrease in IL-2 production in both
PBMCs and inferior turbinate tissue (Fig 1A and 1B), while only the maximal concentration of
compound A (10μM) is capable of significantly, but forcefully, repressing IL-2, and only in
PBMCs (Fig 1A). Furthermore, we discovered that in PBMCs and inferior turbinate tissue a
low concentration of compound A (0.1μM) could synergistically elevate the already SEB-stim-
ulated IFN-γ production (Fig 1C and 1D). However, a higher concentration of compound A
(10μM) antagonistically imposed a strong repression on INF-γ production in these PMBCs
(Fig 1C). A similar profile, though less pronounced is also observed for SEB- and MP-treated
inferior turbinate tissue (Fig 1D). Although this stimulatory trend appears also in SEB-stimu-
lated MP-treated PBMCs, the response is not pronounced enough to reach significance, but
MP at 10μM does repress SEB-stimulated IFN-γ production in PMBCs (Fig 1C). To summa-
rize, both compound A and MP can repress IL-2 and IFN-γ production, while lower concentra-
tions of compound A (0.1μM, 1μM) can enhance the secreted levels of IFN-γ from PBMCs.
The impact of compound A and methylprednisolone on Th2 cytokines
To analyze how Th2 cytokines would respond when exposed to compound A, we measured the
production of IL-5, and IL-10 in the experimental setting as detailed above. The exposure of
PBMCs to SEB results in an increase in IL-5 production (Fig 2A). While SEB could also induce
a positive trend in IL-5 production in inferior turbinate tissue, this trend does not reach signifi-
cance (Fig 2B). Our results further show that in PBMCs MP can significantly repress IL-5 se-
cretion, while compound A can only achieve this at a higher concentration (10μM) (Fig 2A).
Compound A is, however, not able to repress IL-5 production in inferior turbinate tissue (Fig
2D).
Since the cytokine IL-10 is produced by Th2 cells, but capable of inhibiting Th1 activity, we
were also interested in how our selective GR agonist would affect its production. Of note, IL-10
can also be secreted by regulatory T cells. We observed that SEB is unable to significantly ele-
vate the IL-10 levels in PBMCs (Fig 2C). Surprisingly, we observed an inverse concentration
gradient for MP stimulation of IL-10 in which MP 0.1μM and MP 1μM cause a steep increase
in PBMC IL-10 production, while MP 10μM actually modestly decreases SEB-stimulated IL-10
Compound A vsMethylprednisolone Effects in Human Tissue
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production (Fig 2C). In a similar trend, a treatment with compound A also brings about an in-
verse concentration gradient stimulation of IL-10 secretion in PBMCs. This compound A
(0.1μM)-augmented IL-10 production is even more pronounced than the stimulation achieved
by MP (0.1μM), with and without addition of SEB (Fig 2C). Notwithstanding the inverse con-
centration gradients for MP and compound A, the addition of SEB remains able to significantly
stimulate the IL-10 production even further. Exemplary, the condition treated with SEB and
MP 0.1μM is significantly higher than the condition with MP 0.1μM alone (P<0.01) (Fig 2C).
In inferior turbinate tissue the secreted levels of IL-10 hardly surpass threshold measurements.
Nevertheless, the above-mentioned effects observed for PMBCs are also trending in this tissue,
but do not reach overall significance (Fig 2D).
Fig 1. Methylprednisolone and compound A inhibit SEB-induced IL-2 and IFN-γ production with a different and tissue-dependent sensitivity. (A,C)
PBMC cells and (B,D) processed nasal inferior turbinate tissues (IT) were treated with methylprednisolone (MP) (0.1μM, 1μM or 10μM) or compound A
(CpdA) (0.1μM, 1μM or 10μM) for 1h, followed by a 24h incubation with SEB (0.5μg/ml). Cell culture media were analyzed for the presence of IL-2 (A,B) or
IFN-γ (C,D). Averaged results of 10 (PBMC) or 9 (IT) patient samples are shown ± SEM. Statistical analysis was performed using a Wilcoxon matched-pairs
signed-rank test to analyze significance of select condition to condition comparisons. ns, not significant; **, P<0.01.
doi:10.1371/journal.pone.0123068.g001
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The impact of compound A and methylprednisolone on IL-17
Next, we branched out to assay the Th17 cytokine IL-17 and how it is impacted by MP and
compound A in PBMCs and inferior turbinate tissue. As expected [29], SEB stimulation caused
a significant increase in IL-17 secretion from both PBMCs and inferior turbinate tissue (Fig 3).
Both compound A and MP can repress IL-17 production, albeit with a different pharmacologi-
cal profile (Fig 3). In PBMCs, MP represses SEB-induced IL-17 from 0.1 μMMP onwards,
while compound A can only significantly repress SEB-stimulated IL-17 production as of 10 μM
compound A (Fig. 3A). In SEB-treated inferior turbinate tissue, only exposure to MP 1μM and
MP 10μM can impose a significant repression on the IL-17 secretion (Fig 3B).
Fig 2. Methylprednisolone or compound A concentration-dependently impacts IL-10 production in PBMCs, while these compounds inhibit SEB-
induced IL-5 production with a different and tissue-dependent sensitivity. (A,C) PBMC cells and (B,D) processed nasal inferior turbinate tissues (IT)
were treated with methylprednisolone (MP) (0.1μM, 1μM or 10μM) or compound A (CpdA) (0.1μM, 1μM or 10μM) for 1h, followed by a 24h incubation with
SEB (0.5μg/ml). Cell culture media were analyzed for the presence of IL-5 (A,B) or IL-10 (C,D). Averaged results of 10 (PBMC) or 9 (IT) patient samples are
shown ± SEM. Statistical analysis was performed using a Wilcoxon matched-pairs signed-rank test to analyze significance of select condition to condition
comparisons. ns, not significant; *, P<0.05; **, P<0.01.
doi:10.1371/journal.pone.0123068.g002
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The impact of compound A and methylprednisolone on pro-inflammatory
cytokines
In the last panel of cytokine analyses, the effect of MP and compound A on the pro-inflamma-
tory cytokines TNFα, IL-1β and IL-6 was assayed and we observed that these cytokines behave
quite similarly. The secreted levels of both TNFα and IL-1β are significantly augmented in
SEB-treated PBMCs and inferior turbinate tissue, when compared to controls (Fig 4). Further-
more, MP can significantly repress basal and SEB-stimulated TNFα and IL-1β production in a
concentration-dependent manner, albeit less pronounced for IL-1β (Fig 4A–4D). Even so,
compound A can inhibit basal and SEB-stimulated TNFα and IL1β production in a concentra-
tion-dependent manner, with a near to complete abrogation of cytokine production when
PBMCs were treated with compound A at 10μM (Fig 4A and 4C). The TNFα and IL-1β pro-
duction in inferior turbinate tissue was also concentration-dependently diminished by com-
pound A (Fig 4B and 4D). In PBMCs, compound A and MP repress TNFα and IL-1β cytokine
production well below basal control levels (Fig 4A and 4C).
As expected with the applied stimulus, both in PBMCs and inferior turbinate tissue, the pro-
duction of IL-6 cannot be raised by the addition of SEB (Fig 4E and 4F). Nonetheless, MP,
starting from 0.1μM in PBMCs and 1μM in inferior turbinate tissue, can significantly diminish
IL-6 cytokine production (Fig 4E and 4F). Also, compound A, starting from 1μM, can inhibit
IL-6 protein levels in PBMCs, with a complete abrogation of IL-6 production after exposure to
compound A 10μM (Fig 4E), far beyond the baseline level that can be reached using MP. Com-
pound A is, however, not able to repress IL-6 production in inferior turbinate tissue (Fig 4F).
The selective GRmodulator compound A does not affect cell viability of
PBMCs
To complement our assessment of the effects of the non-steroidal selective GR modulator com-
pound A in human cells and tissue, we set out to assay whether this compound could affect cell
viability. The often spectacular drop in PBMC cytokine production associated with a 10μM
Fig 3. Methylprednisolone and compound A inhibit SEB-induced IL-17 production with a different and tissue-dependent sensitivity. (A) PBMC cells
and (B) processed nasal inferior turbinate tissues (IT) were treated with methylprednisolone (MP) (0.1μM, 1μM or 10μM) or compound A (CpdA) (0.1μM, 1μM
or 10μM) for 1h, followed by a 24h incubation with SEB (0.5μg/ml). Cell culture media were analyzed for the presence of IL-17. Averaged results of 10
(PBMC) or 9 (IT) patient samples are shown ± SEM. Statistical analysis was performed using a Wilcoxon matched-pairs signed-rank test to analyze
significance of select condition to condition comparisons. ns, not significant; *, P<0.05; **, P<0.01.
doi:10.1371/journal.pone.0123068.g003
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Fig 4. Methylprednisolone and compound A concentration-dependently inhibit TNFα, IL-1β and IL-6 production with a different and tissue-
dependent sensitivity. (A,C,E) PBMC cells and (B,D,F) processed nasal inferior turbinate tissues (IT) were treated with methylprednisolone (MP) (0.1μM,
1μM or 10μM) or compound A (CpdA) (0.1μM, 1μM or 10μM) for 1h, followed by a 24h incubation with SEB (0.5μg/ml). Cell culture media were analyzed for
the presence of TNFα (A,B), IL-1β (C,D) or IL-6 (E,F). Averaged results of 10 (PBMC) or 9 (IT) patient samples are shown ± SEM. Statistical analysis was
performed using a Wilcoxon matched-pairs signed-rank test to analyze significance of select condition to condition comparisons. ns, not significant; *,
P<0.05; **, P<0.01.
doi:10.1371/journal.pone.0123068.g004
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compound A treatment could lead to suspect a possible effect of this selective GR modulator
on cell survival.
To analyze this, we pretreated PMBCs with solvent or varying concentrations of compound
A either or not followed by SEB, and analyzed the lactate dehydrogenase content of the medi-
um. This oxidoreductase mediates the interconversion of lactate and pyruvate, and is released
into the medium when membrane integrity is lost, thus acting as a measure for cell damage.
The analysis of 10 PBMC patient samples showed no significant differences in LDH activity,
and thus no significant differences in cell damage, between the various treatments and across
the different patient samples (Fig 5A). A dilution test, measuring 1:2 and 1:4 dilutions of select
samples, showed no statistically significant difference between our actual and our theoretically
expected data, indicating that our observations are observed within the linear range (Fig 5B).
In conclusion, compound A (0.1μM, 1μM or 10μM), either or not combined with SEB, does
not impact PBMC cell membrane integrity.
Additionally, we assessed the binding of the phospholipid binding protein annexin V to po-
tentially externalized phophatidylserine residues to the plasma membrane, as a hallmark for a
cell undergoing apoptosis, using flow cytometry gated on the lymphocytes. Propidium iodide is
used as a marker of cell death in this assay. We could show that both MP (10μM) and com-
pound A (10μM) do not significantly impact the annexin V binding and thus induction of apo-
ptosis in the PBMC lymphocytes (Fig 5C). A selection of PBMCs was also exposed to
staurosporine for 24 h, as a positive control. Indeed, staurosporine (10μM) can significantly en-
hance annexin V binding and thus the number of cells showing apoptotic events in the PBMC
lymphocyte fraction (Fig 5C).
RU486 enforces the transrepressing activity of compound A, and
selectively counteracts methylprednisolone’s repressing effects
Lastly, we performed an additional experiment with a different set of PMBCs using compound
A and methylprednisolone and investigated whether their activity could be abrogated or coun-
teracted by the GR and progesterone receptor inhibitor RU486 (also known as mifepristone)
[30,31]. The exact binding mode of compound A on GR remains unresolved; it possibly binds
(differently) within the ligand-binding pocket or not even in the ligand-binding pocket at all.
Additionally, only a partial glucocorticoid displacement can be attained using increasing com-
petition with compound A [21]. Moreover, RU486 on its own can also act as a partial agonist
in both transactivation and transrepression in some cells [32–36]. It may thus potentially par-
tially stimulate the expression of GILZ and DUSP1 in PBMCs and display its own partial trans-
repressing actions on cytokines, and may thus perturb the interpretation of compound A and
RU486 combination experiments even further. Notwithstanding the evidence clouding the
mechanistic interpretation of RU486-based experiments, RU486 is a clinically approved drug
and we were interested to investigate its effects on a methylprednisolone- or compound A-me-
diated regulation of cytokines.
As expected, we could show that RU486 can indeed act as a partial GR agonist in transre-
pression, by itself partially repressing the secretion of monitored cytokines (Fig 6A–6E). Al-
though RU486 was functional in counteracting a classic GRE-regulated gene, namely GILZ, at
2μM [37], RU486 at a 10 fold higher concentration was only able to counteract methylprednis-
olone-mediated repression of IL-5 (Fig 6B), and not of the other monitored cytokines in
PBMCs (Fig 6A and 6C–6E). Likely due to the evidence mentioned above, RU486 could not re-
verse compound A-mediated effects on SEB-stimulated PBMC-secreted cytokines. In fact, the
partial agonistic properties of RU486 even add on to the compound A-mediated repression of
IFNγ, IL-10, IL-17 and IL-1β(Fig 6A and 6C–6E), suggesting that compound A either binds
Compound A vsMethylprednisolone Effects in Human Tissue
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Fig 5. The selective GRmodulator compound A does not affect cell viability of PBMCs. (A) PBMC cells
were treated with compound A (CpdA) (0.1μM, 1μM or 10μM) for 1h, followed by a 24h incubation with SEB
(0.5μg/ml). Cell culture media were analyzed for the presence of LDH. Averaged results of 10 patient
samples are shown ± SEM. Statistical analysis was performed using a Friedman test to compare all samples.
ns, not significant (B) Six selected samples were diluted 1:2 and 1:4 and measured for LDH activity. Results of
the undiluted sample were set as 1 and results of diluted samples were recalculated accordingly to obtain the
‘calculated dilution factor’. The resulting calculated dilution factors are presented as a box and whiskers plot
and graphed against the theoretically expected value, i.e. the dilution factor on the X-axis. (C) PBMCs of 6
Compound A vsMethylprednisolone Effects in Human Tissue
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outside of the GR ligand-binding pocket or acts independently of GR itself. Note that these re-
sults using a different set of patient samples show different sensitivities for SEB onto IL-10 and
for MP onto IL-10, IFN-γ and IL-1β, suggesting a patient-specific sensitivity towards GR re-
sponses and the inflammatory stimulus.
Discussion
In this study we investigated the effects of classic glucocorticoids versus the effects of com-
pound A on the ability of peripheral blood mononuclear cells (PBMCs) (Table 1) as well as in-
ferior turbinate tissue (Table 2) to respond to a challenge with Staphylococcus aureus–derived
enterotoxin B protein (SEB), previously used in an established model to investigate human
nasal polyposis. We could show that both compound A and the tested glucocorticoid can in-
hibit cytokine release and augment the production of the inhibitory cytokine IL-10, albeit with
compound-specific amplitudes.
Although compound A has known cytotoxic effects in a selected variety of immortalized
cancer cell lines [38,39], cell membrane instability LDH analyses of compound A-exposed
PBMCs clearly showed an absence of cell death events in these PBMCs (Fig 5A). Furthermore,
neither compound A nor methylprednisolone could induce apoptosis-indicating annexin V
binding in lymphocytes (Fig 5C). We already knew that glucocorticoids did not have a pro-
found effect on cell viability, as a previous report using transmission electron microscopy, al-
ready demonstrated that PBMCs left untreated or treated with glucocorticoids, in this case
dexamethasone, died at similar rates over a course of 48h [40].
In the current study, all PBMC-secreted cytokines, save IL-6 and IL-10, were significantly
upregulated by SEB stimulation (Table 1 and Figs 1–4), which concurs with current publica-
tions on SEB-induced cytokine production of IL-2, IFN-γ, IL-5, IL-17, TNFα and IL1-β
[41,42]. The inferior turbinate tissue of healthy subjects displayed only a SEB-stimulated signif-
icant increase for the cytokines IL-2, IL-17, TNFα and IL-1β (Figs 1, 3 and 4), whilst also IFN-γ
and IL-10 have been reported to significantly increase in this tissue after SEB exposure [27].
Similarly, nasal polyp tissue displays a SEB-stimulated significant release of IL-1, TNFα, IFN-γ,
IL-2, IL-5 and IL-17 [28]. As enterotoxins act as superantigens via polyclonal T cell activation
[43], the lack of a SEB-mediated stimulus on IL-6 production, mainly by monocytes, was to be
expected (Fig 4E and 4F). A remarkable tissue-dependent response difference does occur for
IFN-γ. In PBMCs, SEB induces an 8-fold increase in IFN-γ production, whereas in inferior tur-
binate tissue the SEB-stimulated IFN-γ hardly surpasses the detection threshold, even after
stimulation. Overall, our data indicate that SEB is capable of stimulating all prominent T helper
cell populations.
Th1, Th2 and also Th17 cells were reported to be implicated in chronic diseases of the para-
nasal sinuses, Th1-related cytokine IFN-γ and Th2-related cytokines IL-4 and IL-5 in chronic
rhinosinusitis without and with nasal polyps, respectively, and more recently Th17-cell-related
IL-17 in nasal polyps [44–46]. Hence, to effectively tackle inflammation, one requires a drug af-
fecting a wide range of activities in different T cell populations. Exposure to glucocorticoids in
the early activation phase of T-cells procures an inhibition of IL-2 and IFN-γ production,
whilst stimulating the cytokine IL-10, expected to inhibit a Th1 response. In acute treatment
patients were exposed to solvent, methylprednisolone (MP) (10μM) or compound A (CpdA) (10μM). PBMCs
of 4 patients were exposed to staurosporine (STS) (10μM) for 24 h, as a positive control. Cell apoptosis and
cell death was analyzed using flow cytometric analysis gated on the lymphocytes, of annexin V binding and
propidium iodide staining, respectively. Averaged results are shown ± SEM. Statistical analysis was
performed using a two-way ANOVA with Bonferroni post-tests to analyze the significance of treatments
versus the solvent control. ns, not significant; **, P<0.01; ***, P<0.001.
doi:10.1371/journal.pone.0123068.g005
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Fig 6. RU486 enforces the transrepressing activity of compound A, and selectively counteracts methylprednisolone’s repressing effects. PBMC
cells were pretreated with solvent or RU486 (RU) (20μM) for 30 minutes, followed by a treatment with solvent, methylprednisolone (MP) (1μM) or compound
A (CpdA) (10μM) for 1h, either or not ensued by a 24h incubation with SEB (0.5μg/ml). Cell culture media were analyzed for the presence of IFN-γ (A), IL-5
(B), IL-10 (C), IL-17 (D), IL-1β (E). Averaged results of 6 patient samples are shown ± SEM. Statistical analysis was performed using aWilcoxon matched-pairs
signed-rank test to analyze significance of select condition to condition comparisons. ns, not significant; *, P<0.05.
doi:10.1371/journal.pone.0123068.g006
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Table 1. Summary of the significant effects of the selective GRmodulator compound A and the glucocorticoid methylprednisolone on PBMCs.
SEB a MP b /SEB CpdA c /SEB
Direction Direction Concentration Direction Concentration
IL d -2 % & 0.1 μM & 10 μM
IFN e -γ % & 10 μM % 0.1 μM
& 10 μM
IL-5 % & 0.1 μM & 10 μM
IL-10 Ns % 0.1 μM % 0.1 μM
& 10 μM & 10 μM
IL-17 % & 0.1 μM & 10 μM
TNF f -α % & 0.1 μM & 1 μM
IL-1β % & 1 μM & 1 μM
IL-6 ns & 0.1 μM & 1 μM
a SEB, Staphylococcus aureus–derived enterotoxin B protein
b MP, methylprednisolone
c CpdA, compound A
d IL, interleukin
e IFN, interferon
f TNF, tumor necrosis factor
A difference was considered signiﬁcant as of P<0.05 and its directionality is indicated with upward (%) or downward (&) arrows. For the concentration
ranges of methylprednisolone and compound A, we also provide the minimal concentration to achieve the respective signiﬁcant effect.
doi:10.1371/journal.pone.0123068.t001
Table 2. Summary of the significant effects of the selective GRmodulator compound A and the glucocorticoid methylprednisolone on inferior tur-
binate tissue.
SEB a MP b /SEB CpdA c /SEB
Direction Direction Concentration Direction Concentration
IL d -2 % & 1 μM ns
IFN e -γ ns % 0.1 μM % 0.1 μM
& 10 μM
IL-5 ns ns ns
IL-10 ns ns % 0.1 μM
IL-17 % & 1 μM ns
TNF f -α % & 0.1 μM & 1 μM
IL-1β % & 0.1 μM & 10 μM
IL-6 ns & 1 μM ns
a SEB, Staphylococcus aureus–derived enterotoxin B protein
b MP, methylprednisolone
c CpdA, compound A
d IL, interleukin
e IFN, interferon
f TNF, tumor necrosis factor
A difference was considered signiﬁcant as of P<0.05 and its directionality is indicated with upward (%) or downward (&) arrows. For the concentration
ranges of methylprednisolone and compound A, we also provide the minimal concentration to achieve the respective signiﬁcant effect.
doi:10.1371/journal.pone.0123068.t002
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regimens however, the production of both IL-4 and IL-5 is also inhibited by glucocorticoids, as
such impeding a Th2 response. In analogy, compound A has been shown to inhibit the OVA-
induced IL-4 and IL-5 Th2 cytokine production in bronchoalveolar lavage fluid in a murine
model of OVA-induced asthma [47]. Taken together, the clinical applicability of glucocorti-
coids expands from auto-immune disease to the treatment of asthma and allergies [48,49]. The
myriad of glucocorticoid effects in immune cells and disorders is also clearly affected by a cross
talk between cytokines and glucocorticoid action [50,51], with cytokines negatively affecting
the activity of the glucocorticoid receptor. Although intricate and currently incompletely re-
solved, researchers have started addressing this conundrum already many decades ago. Howev-
er, for compound A the picture is currently far less clear.
From in vivomurine and in vitro experiments using compound A, we know that this selec-
tive GR modulator actively favors the formation of GR monomers and as such precludes classic
GRE stimulation of side-effect associated genes, but also of anti-inflammatory genes such as
GILZ. Similar to classic glucocorticoids, compound A has NF-κB-dependent anti-inflammato-
ry properties exerted by inhibiting pro-inflammatory gene expression [21,22, 23, 52]. Here, we
show that both compound A and the glucocorticoid methylprednisolone are capable of re-
pressing IL-2, IFN-γ, IL-5, IL-6, IL-10, IL-17, IL-1β and TNFα expression in human PBMCs
(Table 1 and Figs 1–4), suggestive of a general anti-inflammatory action profile. In the inferior
turbinate tissue, treatment with methylprednisolone could significantly repress IL-2, IFN-γ, IL-
6, IL-17, TNFα and IL-1β production, while a compound A treatment only allowed for a signif-
icant repression of IL-1β and TNFα (Table 2 and Figs 1–4). Overall, the compound A-induced
repression window of cytokines showed to be far greater in PBMCs than in inferior turbinate
tissue. However, this could be explained as in our results PBMCs generally express higher cyto-
kine levels than samples of inferior turbinate tissue, except for IL-6, in which the inferior turbi-
nate tissue levels exceed PBMC levels, and IL-17, which appears to be produced in a similar
range in both experimental settings. Furthermore, we noticed the resemblance in the IL-2, and
IL-17 responses to compound A in PBMCs, which did not show any effect for compound A
1μM, while displaying a clearly abrogated cytokine production after exposure to compound A
10μM (Fig 1 and 3). Although we report a slightly more sensitive and more gradual response
profile for IL-6, TNFα and IL-1β (Fig 4), all cytokines showed a steep decline to near or below
baseline levels at compound A 10μM.
Interestingly, both IFN-γ and IL-10 seem to respond differently to methylprednisolone and
compound A, depending on the administered concentration. Low concentrations of the selec-
tive GR modulator compound A result in a surge of IFN-γ and IL-10 levels, while high concen-
trations of compound A actually result in a decrease in IFN-γ and IL-10 levels in PBMCs (Figs
1C and 2C).When using the classic glucocorticoid methylprednisolone, this response profile is
reiterated, albeit in a milder form (Figs 1C and 2C). Of note, IFN-γ was previously shown to be
able to inhibit Th2 cytokine production and IL-10 can inhibit a Th1 response [48]. Moreover,
IL-10 can act as a sensitizer for glucocorticoid responsiveness [51].
Although compound A is unable to stimulate classic GRE-regulated gene transcription [21],
recent publications on compound A-stimulated gene expression of Hsp70 [53] and on com-
pound A-mediated stimulation of the transcription factor GATA-3 [54], together with our cur-
rent report on a compound A-mediated increase in IFN-γ and IL-10 production, support the
notion that compound A can stimulate gene transcription via alternate mechanisms. Often,
but not always, these mechanisms are also utilized by classic glucocorticoids and the GR. Given
the fact that compound A has shown both GR-dependent and GR-independent mechanisms in
previous reports [21,47,52,55,56], we cannot exclude compound A-mediated GR-independent
effects. However, we wish to emphasize that all compound A-mediated effects on cytokine and
chemokine repression thus far have shown to be mediated via GR, using full GR knockdown or
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knockout approaches [21,47,52,55]. Combining this insight with the additive repressive effect
of RU486 and compound A on PBMC cytokine levels, suggests that compound A represses cy-
tokine levels via a GR-mediated mechanism, but may either bind within or outside the ligand-
binding pocket of GR in a differential manner. In support, compound A induces a different,
currently unclarified, conformational change of GR [21]. Although in silicomodeling mapped
compound A to fit the ligand-binding pocket of GR [39], other modes of binding cannot be ex-
cluded, because we still await the first elucidated crystal structure of this particular selective GR
modulator binding to the GR ligand-binding domain.
Furthermore, the concept of glucocorticoid concentration-dependent effects on gene ex-
pression have been noticed previously in other settings, but remains often unexplained [57–
59]. Although pharmacological response profile analyses are commonly performed using a
range of concentrations, mechanistic studies are still quite often limited to one concentration.
For instance, in murine T-cells it was earlier reported that a 10μM concentration of compound
A can diminish IFN-γ levels via an inhibition of the transcription factor T-bet [54]. However,
the authors did not investigate the effect of lower concentrations of compound A on the Th1
cytokine IFN-γ. Nevertheless, their results do suggest that a low concentration compound A-
mediated upregulation of IFN-γ, if any in this system, would probably not stem from a stimula-
tion of T-bet [54]. A species-specific event on PBMC cannot be excluded, as in vivo compound
A-treated murine PBMCs also show diminished IFN-γ levels [60]. In conclusion, the interplay
of Th1 and Th2 immunity under the influence of a selective GR modulator deserves
further investigation.
In conclusion, both the glucocorticoid methylprednisolone, and the novel selective GR
modulator compound A display anti-inflammatory actions in both ex vivo PBMC and a nasal
tissue stimulation model of nasal polyposis. Combining compound A ‘s established improved
side effect profile pertaining to bone and glucose metabolism together with our current results,
allows to advise further research into a novel generation of more stabile selective GR modula-
tors as a new anti-inflammatory therapy in clinic to evaluate their therapeutic benefit.
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